Hope you're right. I'm holding too. I want to at least hear blood test results from FX. I believe Dr Traber said they were forthcoming. I think if Alpha2 macroglobulin continued the trend downward and maybe other serum markers, then GR-MD-02 is still in play.
What I don't like:
• No testing of dosage over current highest dose. I don't understand the reasoning why this wasn't explored. What if efficacy increases further with a higher (or more frequent) dose? It's crazy to leave this door closed in my opinion.
• Melanoma trial could be our savior but the sample size is tiny and the market may not be impressed.
• I'm stuck at this point. Half my shares are in warrants that are so in the hole it isn't funny. For what I could get for my shares now, I'm willing to let it ride and take the loss if it should happen. Wish they could extend the term for the warrants until after CX results. (does that ever happen?)
• That retention bonus for two of the employees several months ago was, in my mind, pretty slimy. I should have listened to myself and not added after that or at least pulled some out just prior to FX results. Those bonuses indicate to me that the lackluster (or at the least unclear/uncertain) results of FX was expected.
I hope we get some good results soon and that there's a buyout-maybe just an exchange of shares. Galectin-3 blocking has shown so much potential in treatment for several indications I'd like to think that some big pharma might grab it up just based on potential. While I think some of the criticism has been overblown, I would welcome a different management/strategy at this point. I think the drug and the trials may need a fresh approach.
Edit to add: And WTF is with these presentations coming up? Maybe there's some new info about the trial but I suspect it's just more "Traber blather".
